期刊
JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES
卷 50, 期 4, 页码 S41-S44出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmir.2019.07.006
关键词
Alpha targeted therapy; radioimmunotherapy; antibody; pretargeting
资金
- Ludwig Center for Cancer Immunotherapy, MSK
- NIH/NCI Cancer Center Support Grant [P30 CA008748]
Radiolabeled antibodies allow for selective targeting of the cancer cells within a tumor. Both beta-and alpha-emitting radioisotopes can be linked to the antibodies for delivery of radiation to the cells. The choice of the radionuclide would depend on the biological characteristics of the antibody including its biodistribution and biological half-life. Alpha-emitting isotopes deliver high energy to target sites within short range and therefore less radiation to adjacent normal tissues. Whole antibodies have long biological clearance times that may be limiting due to radiation levels to blood and marrow. Novel strategies, such as development of smaller antibody fragments such as minibodies and diabodies, which have faster biological clearance, engineered bispecific antibodies, and multistep targeting that uses pre-targeting and bioorthogonal click chemistry methods, appear promising. Several novel targets are being investigated in early-phase studies. This review provides a brief summary and current status of radioimmunotargeted agents in oncology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据